We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Thermo Fisher Scientific - Direct Effect Media

Download Mobile App





Clinical Trial to Study Effects of Steroid-Cannabidiol (CBD) Treatment on Hospitalized COVID-19 Patients

By HospiMedica International staff writers
Posted on 02 May 2020
Print article
Image: Rabin Medical Center (Photo courtesy of Wikimedia Commons).
Image: Rabin Medical Center (Photo courtesy of Wikimedia Commons).
A small-scale clinical trial is currently underway to evaluate the use of Cannabidiol (CBD) for the treatment of hospitalized patients with COVID-19 infection.

The clinical trial is being held by STERO Biotechs Ltd. (Bnei Brak, Israel), a clinical-stage company focused on CBD formulation research and development, in collaboration with Mor Research Applications, the Tech Transfer Office (TTO) of the largest Health Maintenance Organization (HMO) in Israel – Clalit. The small-scale clinical trial is being held at Rabin Medical Center Golda HaSharon Campus, treating 10 patients as a 'POC' with the aim of benefitting and helping hospitalized patients with COVID-19 infection.

Steroid treatment is usually the first or second line of treatment for hospitalized patients. CBD enhances the therapeutic effect of steroid treatment and treats the bio-mechanism affected by the virus. The initial study will evaluate the tolerability, safety, and efficacy of the CBD treatment, for hospitalized patients with COVID-19 infection. The treatment cycle will be for a few weeks with a subsequent follow-up period of the same length. Under Stero's allowed IP and pending the success of the 'POC', the company plans to scale up and expand to a phase 2a multi-center clinical trial, with an additional 40 hospitalized patients with COVID-19 infection, under FDA clinical trial guidelines and regulations.

“We estimate that our CBD-based treatment can enhance the current treatment of those patients who are in life-threatening conditions,” said David Bassa, Founder & CEO of Stero Biotechs. “Hospitalized COVID-19 patients are mostly being treated with steroids and our study is planned to demonstrate the benefit of a combined solution with steroid treatments. We are hopeful that this study will lead to faster benefit for the growing number of COVID-19 patients in Israel and around the world.”

Related Links:
STERO Biotechs Ltd.


Print article

Channels

Critical Care

view channel
Image: EsoGuard has demonstrated over 90% specificity and 90% sensitivity in identifying Barrett’s Esophagus (Photo courtesy of Lucid Diagnostics)

Biomarker Based Non-Endoscopic Technology Identifies Risk for Esophageal Cancer

Barrett's esophagus (BE) is the benign and treatable precursor condition to esophageal adenocarcinomas (EAC) which is usually diagnosed at an advanced stage and is difficult to treat. Finding BE, a sign... Read more

Surgical Techniques

view channel
Image: Novel surface treatment could prevent deadly hospital infections without antibiotics (Photo courtesy of Penn State)

Novel Surface Treatment Stops Microbes from Adhering to Medical Devices

Hospitals and medical clinics can be the source of nasty infections, resulting in death from infection-related complications and billions in direct medical costs. The biggest culprits, experts say - accounting... Read more

Patient Care

view channel
Image: Future wearable health tech could measure gases released from skin (Photo courtesy of Pexels)

Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases

Most research on measuring human biomarkers, which are measures of a body’s health, rely on electrical signals to sense the chemicals excreted in sweat. But sensors that rely on perspiration often require... Read more

Health IT

view channel
Image: AI can reveal a patient`s heart health (Photo courtesy of Mayo Clinic)

AI Trained for Specific Vocal Biomarkers Could Accurately Predict Coronary Artery Disease

Earlier studies have examined the use of voice analysis for identifying voice markers associated with coronary artery disease (CAD) and heart failure. Other research groups have explored the use of similar... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.